Top-News

Moleculin Aktie News

Aktie
WKN:  A41SET ISIN:  US60855D4088 US-Symbol:  MBRX
5,13 $
+0,3 $
+6,21%
4,3628 € 17:58:31 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

Moleculin News

21.10.25 - PR Newswire
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Beyond Traditional Drugs: Novel Platforms Targeting Hard-​to-Treat Conditions PR Newswire
21.10.25 - PR Newswire
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Beyond Traditional Drugs: Novel Platforms Targeting Hard-​to-Treat Conditions PR Newswire
11.03.25 - PR Newswire
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference PR Newswire
10.03.25 - PR Newswire
Moleculin to Present at the 37th Annual ROTH Conference
Moleculin to Present at the 37th Annual ROTH Conference PR Newswire
06.03.25 - PR Newswire
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity PR Newswire
03.03.25 - PR Newswire
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium PR Newswire
25.02.25 - PR Newswire
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules PR Newswire
13.02.25 - PR Newswire
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds PR Newswire
13.02.25 - PR Newswire
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-​Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) PR Newswire
11.02.25 - PR Newswire
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial PR Newswire
27.01.25 - PR Newswire
Moleculin Participates in Virtual Investor "What This Means" Segment
Moleculin Participates in Virtual Investor "What This Means" Segment PR Newswire
08.01.25 - PR Newswire
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-​Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 PR Newswire
11.12.24 - PR Newswire
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model PR Newswire

Newssuche

Videos

newspaper
10:40 Uhr +0,93%
Technical Trading: Zucker Long zum Jahresende
Zucker Long Typ: Turbo Open End WKN: VP89SL Hebel: 5,88 Laufzeit: OpenEnd Einstieg: Market ... Mehr »